Nebratamig

尼布妥米单抗

Report date: 2026/03/19 17:22:43

Base Information

Drug NameNebratamig
Drug Alias NameGNC-035
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Tetraspecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionInactive tyrosine-protein kinase transmembrane receptor ROR1 antagonistsProgrammed death-ligand 1 blockersTumor necrosis factor receptor superfamily member 9 agonists +[5] 
TargetsInactive tyrosine-protein kinase transmembrane receptor ROR1Programmed death-ligand 1T cell surface glycoprotein CD3 +[4] 
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursHematologic Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSichuan Baili Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBaili-Bio (Chengdu) Pharmaceutical Co LtdSystImmuneSichuan Baili Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerHematologic NeoplasmsBreast Neoplasms +[5] 
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A